Living With the Burden of Pseudobulbar Affect: A Qualitative Analysis of the Effects of Education on Patient Experience.

mixed methods evaluation research online education patient experience pseudobulbar affect

Journal

Journal of patient experience
ISSN: 2374-3735
Titre abrégé: J Patient Exp
Pays: United States
ID NLM: 101688338

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 18 1 2021
pubmed: 19 1 2021
medline: 19 1 2021
Statut: ppublish

Résumé

Pseudobulbar affect (PBA) is associated with several neurological diseases and is underrecognized in clinical practice; however, PBA symptoms are often attributed to psychiatric or mood disorders rather than to neurological etiology. Until recently, there were no US Food and Drug Administration therapies approved for treating this condition, and there are currently few resources to support patients in the recognition and self-management of PBA symptoms. We evaluated the impact of a virtual education symposium on patient knowledge and self-efficacy via qualitative interviews. This evaluation of education impact provides unique insight into the experience of managing PBA symptoms; suggests that there is extensive need for educational resources to support patients with PBA and enable them to engage effectively with their providers; and affirms that online learning is an effective mechanism for delivering education to patients that enables them to more effectively self-manage symptoms in the context of chronic neurological conditions such as PBA.

Identifiants

pubmed: 33457582
doi: 10.1177/2374373519899597
pii: 10.1177_2374373519899597
pmc: PMC7786644
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1324-1330

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Erik Pioro has received consulting fees from Avanir Pharmaceuticals.

Références

Expert Rev Neurother. 2011 Jul;11(7):1077-88
pubmed: 21539437
J Affect Disord. 2016 Jan 15;190:150-155
pubmed: 26519634
Adv Ther. 2011 Jul;28(7):586-601
pubmed: 21660634
BMJ. 2000 Jan 8;320(7227):114-6
pubmed: 10625273
Neurology. 2009 Oct 13;73(15):1227-33
pubmed: 19822873
Ann Neurol. 2007 Feb;61(2):92-6
pubmed: 17212357
PLoS One. 2013 Aug 21;8(8):e72232
pubmed: 23991068
BMC Health Serv Res. 2014 Aug 27;14:356
pubmed: 25164529
Adv Ther. 2012 Sep;29(9):775-98
pubmed: 22941524
Ther Clin Risk Manag. 2013;9:483-9
pubmed: 24348042
J Neurol Neurosurg Psychiatry. 1998 Dec;65(6):928-9
pubmed: 9854975

Auteurs

Wendy Turell (W)

CME Outcomes and Analytics, PlatformQ Health Education, Needham, MA, USA.

Anne Roc (A)

Medical Education and Strategy, PlatformQ Health Education, Needham, MA, USA.

Erik Pioro (E)

Section of ALS & Related Disorders, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA.

Alexandra Howson (A)

Thistle Editorial, LLC, Snoqualmie, WA, USA.

Classifications MeSH